MedTrace Logo

RIsk of Apoplexia Cerebri in CLOpidogrel Non-responders

NCT02093299 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 165

Last updated 2017-07-02

No results posted yet for this study

Summary

Stroke patients are given prophylactic treatment with clopidogrel to prevent new strokes. Some of these patients (the investigators don't know precisely how many, but previous studies indicate 4-34%) are so called non-responders, when you measure on a blood sample from the patient. These patients may have an increased risk for less effect of the treatment and therefore a higher risk for a new stroke.

The investigators want to investigate if clopidogrel non-responders have a clinically increased risk of a new stroke by following the patients for two years. With this study the investigators aim to ensure that all patients get the best prophylactic treatment and reduce the risk of early death and dependency of others.

Conditions

Interventions

DRUG

Clopidogrel

a blood sample is drawn on all patients to determine responder status

Sponsors & Collaborators

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Charlotte Rath, MD · Dept. of Neurology Roskilde University Hospital

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2016-11-22
Completion
2016-11-22

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02093299 on ClinicalTrials.gov